Evaluation of 3TC or FTC Mono-therapy Compared to Continuing HAART as a Bridging Strategy (P1094)
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
| Study Type: | Interventional |
|---|---|
| Study Design: | Allocation: Randomized; Endpoint Classification: Safety/Efficacy Study; Intervention Model: Parallel Assignment; Masking: Open Label; Primary Purpose: Treatment |
| Condition: |
HIV Disease |
| Interventions: |
Drug: HAART regimen Drug: 3TC or FTC monotherapy |
Participant Flow
Hide Participant Flow
Recruitment Details
| Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations |
|---|
| Participants were recruited from 17 sites in the United States, Argentina, Brazil and Thailand. Enrollment occurred from May 10, 2011 to January 16, 2013. |
Pre-Assignment Details
| Significant events and approaches for the overall study following participant enrollment, but prior to group assignment |
|---|
| Eligible participants were HIV-infected, ≥8 to <25 years of age with documentation of the M184V HIV resistance mutation, were failing their current antiretroviral regimen and were persistently non-adherent. Participants were randomized equally to the two study arms. |
Reporting Groups
| Description | |
|---|---|
| Arm A, Non-suppressive HAART Regimen |
In Step 1, subjects were randomized to continue their non-suppressive HAART regimen. In Step 2, subjects either began a new HAART regimen, continue randomized treatment, or discontinued therapy while remaining on follow-up, as decided by their provider. HAART regimen: The study participant continued their non-suppressive HAART regimen as prescribed by their primary provider. |
| Arm B, 3TC or FTC Monotherapy |
In step 1, subjects were randomized to receive 3TC or FTC (the choice of 3TC or FTC was left to the provider.) In Step 2, subjects either began a new HAART regimen, continue randomized treatment, or discontinue therapy while remaining on follow-up, as decided by their provider. 3TC or FTC monotherapy: The study participant was assigned to either 3TC or FTC monotherapy (the choice of 3TC or FTC was left to the provider.) |
Participant Flow: Overall Study
| Arm A, Non-suppressive HAART Regimen | Arm B, 3TC or FTC Monotherapy | |
|---|---|---|
| STARTED | 16 | 17 |
| COMPLETED | 5 | 6 |
| NOT COMPLETED | 11 | 11 |
| Unexpected closure of study | 10 | 9 |
| Withdrawal by Subject | 0 | 2 |
| Found ineligible after starting | 1 | 0 |
Baseline Characteristics
Population Description
| Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate. |
|---|
| All participants who entered the study were included in analyses. |
Reporting Groups
| Description | |
|---|---|
| Arm A, Non-suppressive HAART Regimen |
In Step 1, subjects will be randomized to continue their non-suppressive HAART regimen as prescribed by their primary provider. In Step 2, subjects will either begin a new HAART regimen, continue randomized treatment, or discontinue therapy while remaining on follow-up, as decided by their provider. |
| Arm B, 3TC or FTC Monotherapy |
In step 1, subjects will be randomized to receive 3TC or FTC (the choice of 3TC or FTC will be left to the provider). In Step 2, subjects will either begin a new HAART regimen, continue randomized treatment, or discontinue therapy while remaining on follow-up, as decided by their provider. |
| Total | Total of all reporting groups |
Baseline Measures
| Arm A, Non-suppressive HAART Regimen | Arm B, 3TC or FTC Monotherapy | Total | |
|---|---|---|---|
|
Number of Participants
[units: participants] |
16 | 17 | 33 |
|
Age
[units: participants] |
|||
| <=18 years | 10 | 11 | 21 |
| Between 18 and 65 years | 6 | 6 | 12 |
| >=65 years | 0 | 0 | 0 |
|
Gender
[units: participants] |
|||
| Female | 12 | 10 | 22 |
| Male | 4 | 7 | 11 |
|
Ethnicity (NIH/OMB)
[units: participants] |
|||
| Hispanic or Latino | 6 | 8 | 14 |
| Not Hispanic or Latino | 9 | 9 | 18 |
| Unknown or Not Reported | 1 | 0 | 1 |
|
Race (NIH/OMB)
[units: participants] |
|||
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 3 | 3 | 6 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 9 | 8 | 17 |
| White | 4 | 6 | 10 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
|
Region of Enrollment
[units: participants] |
|||
| United States | 9 | 9 | 18 |
| Argentina | 2 | 1 | 3 |
| Brazil | 2 | 4 | 6 |
| Thailand | 3 | 3 | 6 |
|
Screening CD4 count
[units: cells/mm3] Median ( Inter-Quartile Range ) |
490
( 377 to 615 ) |
461
( 384 to 683 ) |
472
( 384 to 651 ) |
|
HIV-1 RNA viral load
[units: log10 copies/mL] Median ( Inter-Quartile Range ) |
4.1
( 3.3 to 4.8 ) |
4.0
( 3.2 to 4.1 ) |
4.0
( 3.2 to 4.5 ) |
Outcome Measures
| 1. Primary: | Number of Participants With Immunologic Deterioration [ Time Frame: From entry to week 28 ] |
Show Outcome Measure 1
| 2. Secondary: | Change in CD4+ T Cell Count [ Time Frame: Entry to week 28 ] |
| 3. Secondary: | Change in HIV-1 RNA Levels [ Time Frame: 28 Weeks ] |
| 4. Secondary: | Adherence as Measured by 3-day Recall [ Time Frame: 28 Weeks ] |
Limitations and Caveats
| Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data |
|---|
| No text entered. |